The murine monoclonal antibody (MAb), designated DF3, reacts with a 300,000-mol wt mammary epithelial antigen. A sequential double-determinant radioimmunoassay (RIA) has been developed to monitor circulating DF3 antigen. Using this assay, we have demonstrated that 33 of 36 normal women had plasma RIA antigen levels < 150 U/mi. In contrast, 33 of 43 patients (76%) with metastatic breast cancer had RIA DF3 antigen levels _ 150 U/ml. The difference between these two groups was statistically significant (P < 0.001). Similar results have been obtained with a double-determinant enzyme-linked immunoassay (EIA). Only 6 of 111 age-matched normal subjects had EIA DF3 antigens levels _ 30 U/ml, while 42 of 58 patients (72%) with breast cancer had levels equal to or above this value. Thus, similar patterns of specificity are obtained with the EIA or RIA. The elevation of circulating DF3 antigen levels in breast cancer patients has been confirmed by transfer blot assays. MAb DF3 reactivity occurred predominantly with circulating antigens of three different molecular weights ranging from 300,000 to -400,000 mol wt. We also demonstrate that patients with both primary and metastatic breast cancer who were free of detectable disease at the time of sampling have DF3 antigen levels that are similar to those obtained from normal subjects. While patients with hepatoma (27%) and ovarian carcinoma (47%) also had elevated circulating DF3 antigen levels, the results suggest that DF3 antigen levels may be useful in distinguishing breast cancer patients from those with esophageal, gastric, colorectal, pancreatic, and lung carcinomas. Furthermore, the results of the RIA, EIA, and transblot analyses demonstrate that the measurement of circulating DF3 antigen levels provides a new and potentially useful marker to follow the clinical course of patients with metastatic breast cancer.
Introduction
We have previously defined a human mammary epithelial antigen using a murine monoclonal antibody, designated DF3 (MAb DF3),' prepared against a membrane-enriched fraction of a human breast carcinoma (1) . This antigen has a molecular weight of 300,000 and is detectable on the surface of human breast carcinoma cells. Immunoperoxidase staining patterns with MAb DF3 clearly distinguish malignant and benign breast lesions. DF3 antigen is present on apical borders of secretory mammary epithelial cells and in the cytosol of less differentiated malignant cells. This apical and cytoplasmic staining pattern of human mammary epithelium has also been described using antibodies produced against milk fat globule membrane (2, 3) and breast carcinoma cells (4) . MAb DF3, however, can be distinguished from other MAbs generated against milk fat globule membrane and breast tumors on the basis of the molecular weight of the cross-reactive antigen (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) .
We have developed two double-determinant immunoassays with MAb DF3 to monitor circulating DF3 antigen levels in patients with breast cancer. DF3 antigen has been assayed in apparently healthy controls, in patients with breast cancer, and in individuals with a prior history of breast cancer but who were free of detectable disease at the time of sampling. The results indicate that DF3 antigen levels are significantly elevated in the plasma and/or serum of patients with breast cancer. These findings have been confirmed by transfer blot analysis. Furthermore, the results indicate that circulating DF3 antigen provides a new and potentially useful marker for following the clinical course of breast cancer.
Methods
Preparation ofMAb DF3. MAb DF3 was produced by the immunization of BALB/c mice with a partially purified membrane-enriched fraction of a human breast carcinoma metastatic to liver (1) . The antibody was purified from ascites by protein A-sepharose-CL-4B (Pharmacia Fine Chemicals, Piscataway, NJ) with elution by a pH gradient at pH 5.5.
The purity of the IgG, was confirmed by SDS polyacrylamide gel electrophoresis.
Sequential DF3 double-determinant radioimmunoassay (RIA). The purified antibody was radiolabeled with Na251I (New England Nuclear, Cambridge, MA) by the Iodogen method (Pierce Chemical Co., Rock- ford, IL) (16) to achieve specific activities of 0.5-0.8 [1'251] (20) .
Results
Plasma samples obtained from patients with metastatic breast cancer and from normal females were diluted and initially assayed for DF3 antigen in the sequential double-determinant RIA. Fig. 1 illustrates representative profiles obtained from the plasma of three patients with breast cancer and two normal females. DF3 antigen was detectable in each plasma. However, the level of DF3 antigen was higher in the patients as compared to controls. For example, DF3 antigen levels were undetectable at a 1:625 dilution of plasma from both normal females, while over 3,000 cpm 125I-MAb DF3 bound at similar dilutions of plasmas from the three patients.
Similar findings have been obtained using the sequential double-determinant EIA. Fig. 2 illustrates representative profiles using this assay. DF3 antigen was detectable in the plasmas from three patients with breast cancer and from three control subjects. However, DF3 antigen levels were undetectable at a 1:125 dilution of plasmas from all three normal females, while significant amounts of peroxidated MAb DF3 bound at similar dilutions of plasmas from the three patients. The EIA profiles thus appeared similar to those obtained by RIA, but this assay was not inhibited at lower plasma dilutions and undetectable plasma DF3 antigen levels were reached at approximately fivefold lower dilutions than in the RIA. Plasma or serum samples yielded identical results.
The detection of circulating DF3 antigen by RIA and EIA prompted further analysis using transblots to determine the molecular weight of the reactive species. Fig. 3 shows the results obtained with plasmas from breast cancer patients and normal subjects. Antigenic heterogeneity was observed in both patients and controls. MAb DF3 reactivity was found predom- Further, the menstrual cycle and pregnancy had no effect on plasma DF3 antigen levels (data not shown). 33 of 36 control subjects had plasma RIA DF3 antigen levels < 150 U/ml (mean±SD; 82±54). In contrast, 33 Fig. 6 . The correlation coefficient for the RIA and EIA data was r2 = 0.77 (P < 0.001). The relationships among assays were extended further by comparing the RIA DF3 antigen levels and those obtained by transblot analysis (58 samples). The correlation between these two determinations was significant (r2 = 0.68, P < 0.001). Similarly, the correlation between the EIA and transblot data (120 samples) was also significant (r2 = 0.49, P < 0.001). The use of the RIA, EIA, or transblot analysis thus provides concordant measurements of DF3 antigen levels. (B) Serial samples (1 Al) from patients shown in Fig. 7 
Discussion
Although circulating levels of carcinoembryonic antigen and gross cystic disease protein are presently used as serologic markers of human breast cancer (21, 22) , there is clearly a need for more specific and sensitive assays. In contrast, tissue markers such as casein (23), a-lactalbumin (24), glycosyltransferases (25) , glycolipids (26) , and phospholipids (27) have been detected in plasma by a variety of techniques, but none has gained acceptance as a breast cancer marker. Human mammary epithelial antigens detected by MAbs prepared against human milk fat globules have been shown to be elevated in sera of patients with disseminated breast cancer (28) . This 46,000-mol wt mammary epithelial antigen is distinct from the 300,000-mol wt antigen reactive with MAb DF3. Similarly, breast epithelial antigens defined by MAb 2417.2 (Mr = 100,000) and by MAb F36/22 (Mr > 400,000) have been detected in increased amounts in the sera of patients with metastatic breast cancer (9, 29 (4), fibrocystic disease (10), fibroadenoma (1) , mastalgia (1) , and physiologic nodularity (4) . § Includes idiopathic (29), associated alcoholic cirrhosis (8), and associated postnecrotic cirrhosis (19) . 11 Includes oat cell (3), adeno (4), and squamous (4). (32) . Furthermore, the degree of breast tumor differentiation has recently been shown to be a determinant of intracellular DF3 antigen content (33) and therefore may also influence circulating levels. Another possibility is that, the presence of breast cancer metastases in nonvisceral organs may not be conducive to secretion of the DF3 antigen. The DF3 antigen may be degraded by the liver. Thus, the presence of intrahepatic metastases could allow shedding of the antigen directly into the systemic circulation. The DF3 antigen is a glycoprotein (unpublished data) and may be susceptible to hepatic degradation. Our studies in metastatic colon cancer suggest that liver metastases are not sufficient to elevate circulating DF3 antigen levels, although cirrhosis or hepatitis can result in elevated values. The findings in cirrhosis and hepatitis could be related to decreased hepatic clearance of the DF3 antigen. Finally, separation of tumor site and burden as independent factors contributing to the elevation of DF3 antigen levels will require a prospective study with objective clinical staging criteria (34, 35) . DF3 antigen levels are thus elevated in 70% of all patients with metastatic breast cancer and in nearly 90% of patients with visceral disease. In contrast, 65 patients with primary and secondary breast cancer who at the time of sampling were considered to be clinically free of disease were monitored for DF3 antigen, and only two of these patients had an elevated level. Further, eight patients with metastatic breast cancer have been monitored during progression of disease and/or response to therapy. In each case, DF3 antigen levels reflected progression or response. These findings suggest that DF3 antigen levels are useful in monitoring the clinical course of breast cancer patients. In contrast, our results do not demonstrate that elevated DF3 antigen levels are specific for the diagnosis of breast cancer. The diagnostic value of monitoring DF3 antigen levels will require extensive investigations that examine plasmas from large numbers of patients with a wide variety of malignancies. Additional studies will also be needed to determine the predictive value of DF3 antigen levels and whether these levels will be useful in monitoring breast cancer recurrence before detection of disease by current diagnostic approaches. 
